Nicotine withdrawal presents a significant challenge for individuals attempting to quit smoking, often leading to relapse without structured support. Therapeutic nicotine replacement therapies (NRTs), specifically nicotine gums, offer a clinically proven solution by managing physiological cravings through controlled nicotine delivery. This article explores the regulatory status and clinical role of these products within the Australian healthcare landscape.
What you'll learn
-
The pharmacological role of nicotine gums as therapeutic agents.
-
The TGA regulatory framework and ARTG inclusion requirements.
-
myduke®’s current clinical position regarding NRT distribution.
-
Evidence-based approaches to smoking cessation, nicotine dependency and professional oversight.
Product Overview: Nicotine Gums as Therapeutic Agents
Nicotine gums are oral pharmacological agents designed to deliver controlled doses of nicotine to the systemic circulation via the buccal mucosa. As a form of nicotine replacement therapy (NRT), these products are specifically formulated to alleviate withdrawal symptoms and support smoking cessation. Unlike recreational nicotine delivery systems, nicotine gums are registered therapeutic goods subject to rigorous safety and efficacy standards.
The Current Regulatory Landscape
In Australia, the Therapeutic Goods Administration (TGA) maintains a strict regulatory framework for NRTs. Nicotine gums are generally available as over-the-counter (OTC) therapeutic goods, provided they are listed on the Australian Register of Therapeutic Goods (ARTG). Inclusion in the ARTG ensures that the product meets high standards for quality and safety, distinguishing these pharmacy-only medicines from unregulated nicotine products that are subject to more restrictive importation controls.
myduke® Position Statement
myduke® frequently receives enquiries regarding the availability of nicotine gums. myduke® currently stocks a range of gums and other NRTs as part of its balanced clinical range. myduke® evaluates emerging clinical evidence and patient requirements to ensure our cessation programs remain at the forefront of evidence-based care.
Clinical Approach to Smoking Cessation and supporting nicotine dependency
Evidence-based smoking cessation and nicotine dependency support requires rigorous, medically supervised intervention. Adherence to clinical guidelines—such as those established by the Royal Australian College of General Practitioners (RACGP)—is essential for successful outcomes. Effective cessation is highly correlated with professional oversight, individualised pharmacotherapy, and behavioural support. Patients are cautioned that using unregulated products may bypass established safety standards and compromise long-term therapeutic objectives.
Final Thoughts & Call to Action
Nicotine gums serve as a valuable tool in the broader landscape of nicotine de-escalation when used within a regulated framework. However, achieving long-term freedom from nicotine dependence is most effectively managed through a structured, medically supervised plan. We encourage readers seeking to transition away from tobacco to consult with a qualified healthcare practitioner to develop an individualised cessation strategy that prioritises safety and clinical efficacy.
Resource Links
For information regarding approved cessation pathways, please consult: